Amenamevir

CAS : 841301-32-4

Ref. 3D-RIB30132

Informations sur le produit

• Nom: Amenamevir
• Synonymes: N-(2-((4-(1,2,4-Oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-N-(2,6-dimethylphenyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide, 2H-Thiopyran-4-carboxamide, N-(2,6-dimethylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide, N-(2,6-Dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl] amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide, N-(2,6-Dimethylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-2H-thiopyran-4-carboxamide 1,1-dioxide, ASP 2151, Amenamevir(ASP 2151), ASP-2151

Description

Amenamevir is a drug used to treat herpes simplex virus (HSV). It is an anti-viral drug that prevents HSV from multiplying. Amenamevir prevents the production of the HSV protein that allows it to attach to and enter human cells. Amenamevir is also active against other viruses, such as hepatitis C and HIV. The chemical structure of amenamevir has been elucidated through X-ray crystallography and nuclear magnetic resonance spectroscopy. Amenamevir has been shown to be effective against HSV-1 in both urine samples and in cell cultures. The antiviral activity of amenamevir may be due to its ability to prevent the virus from attaching itself to a cell's surface, inhibiting viral replication by interfering with the synthesis of viral DNA, or inhibiting the production of proteins essential for assembly of new virus particles.
Amamevir is currently undergoing clinical trials for treatment of hepatic impairment.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 482.55 g/mol
• Formule: C₂₄H₂₆N₄O₅S
• Degré de pureté: Min. 95%